Marketwire -- London, UK; Brentwood, TN, US; 24 September 2008 - Protherics PLC (“Protherics” or the “Company”) the international biopharmaceutical company focused on critical care and cancer, today reports the findings of further analyses of data from its placebo-controlled phase 2b Digibind® (GSK) Efficacy Evaluation in Pre-eclampsia (“DEEP”) study. These new analyses, together with results from a mechanistic study, were presented in two oral presentations at the 16th World Congress of The International Society for the Study of Hypertension in Pregnancy (ISSHP) in Washington DC, US this week.
